TY - JOUR
T1 - Utilizing in vitro drug release assays to predict in vivo drug retention in micelles
AU - Varela-Moreira, Aida
AU - van Leur, Heleen
AU - Krijgsman, Danielle
AU - Ecker, Veronika
AU - Braun, Martina
AU - Buchner, Maike
AU - Fens, Marcel H A M
AU - Hennink, Wim E
AU - Schiffelers, Raymond M
N1 - Funding Information:
This work was funded by Netherlands Organization for Scientific Research (NWO) , High Tech Systems & Materials grant number 13312 .
Publisher Copyright:
© 2022 The Authors
PY - 2022/4/25
Y1 - 2022/4/25
N2 - In the present work, we aim at developing an in vitro release assay to predict circulation times of hydrophobic drugs loaded into polymeric micelles (PM), upon intravenous (i.v.) administration. PM based on poly (ethylene glycol)-b-poly (N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) block copolymer were loaded with a panel of hydrophobic anti-cancer drugs and characterized for size, loading efficiency and release profile in different release media. Circulation times in mice of two selected drugs loaded in PM were evaluated and compared to the in vitro release profile. Release of drugs from PM was evaluated over 7 days in PBS containing Triton X-100 and in PBS containing albumin at physiological concentration (40 g/L). The results were utilized to identify crucial molecular features of the studied hydrophobic drugs leading to better micellar retention. For the best and the worst retained drugs in the in vitro assays (ABT-737 and BCI, respectively), the circulation of free and entrapped drugs into PM was examined after i.v. administration in mice. We found in vivo drug retention at 24 h post-injection similar to the retention found in the in vitro assays. This demonstrates that in vitro release assay in buffers supplemented with albumin, and to a lesser degree Triton X-100, can be employed to predict the in vivo circulation kinetics of drugs loaded in PM. Utilizing media containing acceptor molecules for hydrophobic compounds, provide a first screen to understand the stability of drug-loaded PM in the circulation and, therefore, can contribute to the reduction of animals used for circulation kinetics studies.
AB - In the present work, we aim at developing an in vitro release assay to predict circulation times of hydrophobic drugs loaded into polymeric micelles (PM), upon intravenous (i.v.) administration. PM based on poly (ethylene glycol)-b-poly (N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) block copolymer were loaded with a panel of hydrophobic anti-cancer drugs and characterized for size, loading efficiency and release profile in different release media. Circulation times in mice of two selected drugs loaded in PM were evaluated and compared to the in vitro release profile. Release of drugs from PM was evaluated over 7 days in PBS containing Triton X-100 and in PBS containing albumin at physiological concentration (40 g/L). The results were utilized to identify crucial molecular features of the studied hydrophobic drugs leading to better micellar retention. For the best and the worst retained drugs in the in vitro assays (ABT-737 and BCI, respectively), the circulation of free and entrapped drugs into PM was examined after i.v. administration in mice. We found in vivo drug retention at 24 h post-injection similar to the retention found in the in vitro assays. This demonstrates that in vitro release assay in buffers supplemented with albumin, and to a lesser degree Triton X-100, can be employed to predict the in vivo circulation kinetics of drugs loaded in PM. Utilizing media containing acceptor molecules for hydrophobic compounds, provide a first screen to understand the stability of drug-loaded PM in the circulation and, therefore, can contribute to the reduction of animals used for circulation kinetics studies.
KW - 3R principle
KW - Circulation kinetics
KW - Drug delivery
KW - Hydrophobic drugs
KW - In vitro - in vivo correlation
KW - Polymeric micelles
UR - http://www.scopus.com/inward/record.url?scp=85125944892&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2022.121638
DO - 10.1016/j.ijpharm.2022.121638
M3 - Article
C2 - 35257802
SN - 0378-5173
VL - 618
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 121638
ER -